Veeva Systems' successful enterprise migrations and a 9-to-3 top-20 pharma win advantage over Salesforce reinforce its industry leadership. See why VEEV stock is a Buy.
Veeva Systems: Top-Line Momentum Should Continue To Accelerate (NYSE:VEEV)

24
Veeva Systems' successful enterprise migrations and a 9-to-3 top-20 pharma win advantage over Salesforce reinforce its industry leadership. See why VEEV stock is a Buy.